GlassScriptPhysician profile
Daniel G Simmons
NPI 1134196900
$1,194.43
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45.10 · 2020: $960 · 2021: $117 · 2022: $72.23.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Active Medical, LLC | $901.75 | 2020 | |
| Sanofi Pasteur INC. | $56.61 | 2019-2021 | |
| Sobi, INC | $46.15 | 2020-2021 | |
| Adlon Therapeutics L.P. | $33.24 | 2021 | |
| Cranial Technologies, INC | $33.04 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $30.93 | 2022 | |
| Organon LLC | $24.17 | 2022 | |
| Genentech USA, INC. | $23.03 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $18.61 | 2021 | |
| Tris Pharma INC | $15.08 | 2019 | |
| Glaxosmithkline, LLC. | $11.82 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Simmons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.